Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BiomX ( (PHGE) ) has provided an update.
On March 13, 2026, BiomX amended a warrant originally issued in connection with a December 26, 2025 investment, cutting its term from five years to an expiration date of December 31, 2026 and halving the exercise price from $2.00 to $1.00 per share, while leaving the warrant share count unchanged. The company also updated the formula for cashless exercise to reference the lowest VWAP over the five trading days prior to exercise, a move management says is intended to reduce long-dated warrant overhang, simplify its capital structure, and support a stronger financial profile.
In a March 19, 2026 letter to shareholders, CEO Michael Oster framed the warrant amendment as part of a broader effort to stabilize BiomX’s finances, close high-cost operations such as its Maryland facility, and enforce tighter spending discipline. The company has stepped up engagement with investment banks and institutional investors and is evaluating strategic repositioning opportunities, including potential moves into advanced technology and defense-related markets, in a bid to enhance capital access and long-term value for stakeholders.
The most recent analyst rating on (PHGE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity) and dilution/restructuring risk from recent corporate actions. Technical indicators are moderately supportive and the earnings call shows clinical and regulatory progress, but short runway and program/regulatory setbacks limit upside.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc., listed on the NYSE American under the ticker PHGE, is undergoing a strategic and financial reset under a new leadership team with experience in financial markets, corporate strategy, and large public companies in the energy and defense sectors. The company is working to simplify its capital structure, reduce non-essential costs, and reposition its business focus toward sectors benefiting from strong global demand for advanced technologies, potentially including defense-related applications.
Average Trading Volume: 1,048,889
Technical Sentiment Signal: Sell
Current Market Cap: $8.03M
See more insights into PHGE stock on TipRanks’ Stock Analysis page.